Biomarker Testing for Autoimmune Rheumatic Disease
Customize your policy alerts
Sign up for Molina Healthcare Policy G2022 alerts
Get alerted when Policy G2022 changes without checking for updates manually.
Monitor payer policy activity
Defines Molina Healthcare's coverage criteria and limitations for antinuclear antibody (ANA), extractable nuclear antigen (ENA) panels, rheumatoid arthritis biomarkers (RF, anti‑CCP), dsDNA, and other biomarker panels used in diagnosis and monitoring of systemic autoimmune rheumatic diseases for covered individuals.
No material clinical or coverage changes in this revision.
Coverage Criteria and Clinical Indications
inv-01: Coverage criteria and exclusions
Covered when ALL of the following scenarios apply as specified below:
Covered indications
- ANA screening once during the initial workup for individuals with signs or symptoms of an autoimmune disease.
- Up to two additional ANA tests per lifetime if new or more severe signs or symptoms of an autoimmune disease develop.
- For individuals with an abnormal, raised ANA titer and clinical correlation with an appropriate autoimmune disorder, ENA panel testing of specific autoantibodies meets coverage criteria.
- For individuals with painful and swollen joints suggestive of rheumatoid arthritis (RA), testing for rheumatoid factor (RF) and/or anti-CCP antibodies once during initial workup.
- If initial RF/anti-CCP testing did not result in a diagnosis of RA, up to two additional RF and/or anti-CCP tests per lifetime if symptoms persist or additional RA symptoms develop.
- For individuals with an initial positive ANA test and a diagnosis of systemic autoimmune rheumatic disease, anti-dsDNA testing up to four times per year.
- In individuals with negative or low-positive ANA, certain condition-specific antibody tests meet coverage criteria (e.g., anti-Jo-1 for a clinical myositis subset; anti-SSA in the context of lupus or Sjögren's syndrome).
Not covered / exclusions
- Monitoring of disease using ANA testing or ANA titers does not meet coverage criteria.
- ANA and/or ENA testing for individuals without symptoms suggestive of an autoimmune disorder (including wellness visits or general exams without abnormal findings) does not meet coverage criteria.
- Testing of specific antibodies in the absence of a positive ANA (for situations not specifically listed above) does not meet coverage criteria.
- Serum biomarker panel testing with proprietary algorithms or index scores (for diagnosis, prognosis, or monitoring)—examples include AVISE CTD, AVISE SLE Monitor/Prognostic, AVISE Lupus (CB-CAPs), Vectra DA, PrismRA, aiSLE DX, Early Sjögren's Syndrome Profile—do not meet coverage criteria due to insufficient evidence.
- Serum biomarker panels for diagnosis of RA (e.g., Seronegative RA Profile) or for RA management do not meet coverage criteria.
inv-02: Coverage-relevant clinical criteria and evidence summaries
Appropriate use and limitations for initial and reflex biomarker testing — clinical points and evidence summaries:
Proprietary multianalyte and predictive panels—evidence summary
- Some studies of multianalyte panels (e.g., AVISE MAP/CB-CAP) report improved specificity and impact on diagnosis/treatment decisions in selected cohorts, but overall clinical utility and consensus across studies vary.
- Predictive molecular panels for TNFi response (PrismRA/MSRC) showed high positive predictive value and specificity in validation cohorts (e.g., CERTAIN) but only moderate sensitivity; decision‑impact and modeling studies suggest potential economic and treatment-selection benefits, though these do not establish replacement of clinical judgment.
inv-03: coverage-relevant findings
Guideline positions, validation findings, and practical implications relevant to clinical utility and recommended use of biomarker tests:
PrismRA (MSRC) validation
- CERTAIN prospective study: PrismRA demonstrated PPV 89.7%, specificity 86.8%, sensitivity 50% for predicting TNFi non-response (ACR50 at 6 months).
- Integrated analyses including NETWORK-004 found an increased odds of inadequate response (OR ~4.1) and substantially lower likelihood of remission in predicted non-responders; predictive performance favors high PPV/specificity over sensitivity.
Economic and decision-impact findings
- Modeling projected improved ACR50 in stratified cohorts and a 19% decrease in costs of ineffective treatment when using PrismRA-informed selection.
- Rheumatologist decision-impact surveys indicate clinician interest in predictive technologies and perceived clinical utility; these data complement but do not substitute for guideline endorsement.
MBDA (Vectra DA) performance and limitations
- MBDA algorithm uses 12 protein biomarkers and correlates with DAS28-CRP (r=0.72); categories: ≤29 low, 29–44 moderate, >44 high.
- MBDA has demonstrated prognostic ability for radiographic progression and influenced treatment plans in observational studies (e.g., changed management in ~38% of cases; higher when discordant with clinical assessment), but randomized trial data showed limited responsiveness compared with clinical measures and caution that MBDA should not replace clinical evaluation.
- MBDA scores can be affected by age, BMI/adiposity and comorbidities; adjusted/ leptin‑adjusted MBDA versions have been developed to improve prognostic performance.
Guideline and referral positions
- ACR endorses HEp-2 IIF as the gold standard and recommends not ordering ANA subserologies without a positive ANA and clinical suspicion; ACR RA management guidance does not endorse multibiomarker tests for diagnosis or management.
- NICE recommends testing for RF in suspected RA with synovitis and considering anti-CCP if RF negative and combination therapy is contemplated; refer suspected persistent synovitis for specialist assessment regardless of some blood test results.
inv-04: Coverage-related observations (partial)
Additional observations from guideline sources and billing/code considerations that inform appropriate use:
Billing and coding note
Covered Tests, Codes, and Frequency Limits
| ANA_initial | Once during initial workup (ANA screening) |
| ANA_additional | Up to two additional tests per lifetime if new or more severe signs or symptoms develop |
| RF_ACPA_initial | Once during initial workup (RF and/or anti-CCP) |
| RF_ACPA_additional | Up to two additional tests per lifetime if initial testing did not result in diagnosis and symptoms persist or additional symptoms develop |
| dsDNA_frequency | Up to four (4) times per year for individuals with an initial positive ANA test and a diagnosis of systemic autoimmune rheumatic disease |
| Vectra DA (proprietary) | Serum biomarker panel (Vectra DA) does not meet coverage criteria |
| PrismRA (MSRC) (proprietary) | Serum biomarker panel (PrismRA) does not meet coverage criteria for management of RA |
| AVISE Lupus / AVISE CTD / AVISE SLE Monitor / AVISE SLE Prognostic | Cell-bound complement activation products and AVISE proprietary panels do not meet coverage criteria for SLE diagnosis or monitoring |
| aisle® DX / Early Sjögren's Syndrome Profile / Seronegative Rheumatoid Arthritis Profile | Proprietary serum biomarker panels and other named proprietary panels do not meet coverage criteria |
| ELISA | Enzyme-linked immunosorbent assay (solid-phase assay) |
| Fluorescent microsphere assays | Multiplex fluorescent microsphere immunoassay |
| Chemiluminescence immunoassays (CIA) | Automated chemiluminescence immunoassay methods |
| FEIA | Fluorescence enzyme immunoassay |
| IIF (HEp-2) | Indirect immunofluorescence on HEp-2 cells (reference method) |
| PrismRA (MSRC) | Molecular signature response classifier integrating RNA sequencing features and clinical variables to predict TNFi non-response (reported PPV 89.7%, specificity 86.8%, sensitivity 50%) |
| Modeling/economic impact | PrismRA modeling showed projected ACR50 improvement and 19% decrease in costs of ineffective treatment |
| MBDA_bands | MBDA score: ≤29 = low; 29–44 = moderate; >44 = high |
| MBDA_components | IL-6; TNFRI; VCAM-1; EGF; VEGF-A; YKL-40; MMP-1; MMP-3; CRP; SAA; Leptin; Resistin (12 biomarkers) |
| MBDA_score | Composite algorithmic score reported as disease activity: ≤29 low, 29–44 moderate, >44 high |
| 81490 | Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, prognostic algorithm reported as a disease activity score (Vectra®DA) |
| MBDA_intended | Intended to complement clinical joint evaluation, not replace it; may correlate with DAS28-CRP (r=0.72) |
| 81490 | Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score Proprietary test: Vectra®DA |
| 81599 | Unlisted multianalyte assay with algorithmic analysis |
| 86038 | Antinuclear antibodies (ANA) |
| 86039 | Antinuclear antibodies (ANA); titer |
| 86200 | Cyclic citrullinated peptide (CCP), antibody |
| 86225 | Deoxyribonucleic acid (DNA) antibody; native or double stranded |
| 86235 | Extractable nuclear antigen, antibody to, any method |
| 86430 | Rheumatoid factor; qualitative |
| 86431 | Rheumatoid factor; quantitative |
| 0062U | Proprietary test: SLE-key® Rule Out (biomarkers, algorithm reported with a risk score) |
| Anti-dsDNA high avidity (proprietary) | Referenced: high salt/avidity anti-dsDNA proprietary test (University of Washington/Bio-Rad) |
| Seronegative Rheumatoid Arthritis Panel (proprietary) | Referenced lab-manufacturer: KSL Diagnostics / Beutner Laboratories (proprietary RA panel) |
| CPT_listing_note | Procedure codes in policy are a general reference and may not be all-inclusive |
Provider Requirements, Authorization, and Denial Risks
Prior authorization and allowable testing frequency
Authorize ANA screening once during the initial diagnostic workup for individuals with signs or symptoms of an autoimmune disease; document timing. Permit up to two additional lifetime ANA tests if new or more severe signs or symptoms develop. For individuals with painful and swollen joints suggestive of RA, authorize RF and/or anti-CCP testing once during initial workup; if initial testing did not result in a diagnosis and symptoms persist or additional RA symptoms develop, allow up to two additional lifetime RF/anti-CCP tests. For individuals with an initial positive ANA and an established diagnosis of a systemic autoimmune rheumatic disease, allow anti-dsDNA testing up to four times per year.
- ANA: once during initial workup; up to two additional lifetime tests for new or worsening signs/symptoms.
- RF and/or anti-CCP: once during initial workup; up to two additional lifetime tests if initial testing was nondiagnostic and symptoms persist or progress.
- Anti-dsDNA: up to 4 times per year for individuals with an initial positive ANA and diagnosis of systemic autoimmune rheumatic disease.
Denial risk / exclusions
Do not authorize testing that is intended for monitoring disease activity using ANA titers, routine ANA/ENA testing in asymptomatic individuals or during wellness/general exams, or ordering specific antibody panels in the absence of a positive ANA (except noted condition-specific exceptions). Proprietary serum biomarker panels and multianalyte algorithm/index tests (e.g., AVISE CTD/AVISE Lupus, Vectra DA, PrismRA, Early Sjögren's Profile, aiSLE DX) do not meet coverage criteria.
- ANA titer monitoring: monitoring of disease with ANA testing or ANA titers DOES NOT MEET COVERAGE CRITERIA.
- Asymptomatic screening/wellness: ANA and/or ENA testing for individuals without symptoms or during general exams DOES NOT MEET COVERAGE CRITERIA.
- Specific antibodies without positive ANA: testing of specific antibodies in the absence of a positive ANA generally DOES NOT MEET COVERAGE CRITERIA (except specified exceptions such as anti-Jo-1 or anti-SSA).
- Proprietary panels: serum biomarker panel testing with proprietary algorithms/index scores (e.g., AVISE CTD, AVISE SLE Monitor/Prognostic, Vectra DA, PrismRA, aisle® DX, Early Sjögren's Profile) DOES NOT MEET COVERAGE CRITERIA.
Required clinical documentation to justify specific antibody testing
Document clinical signs, symptoms, and correlation to support ENA or other specific autoantibody testing (for example, an abnormal or raised ANA titer with relevant clinical findings). Ensure documentation records the clinical indication for repeat testing and adherence to frequency limits described in policy.
- Record signs/symptoms that justify initial ANA screening and any subsequent additional ANA tests (new or worsened findings).
- For ENA or specific antibody testing, document an abnormal/raised ANA titer and clinical correlation with an appropriate autoimmune disorder.
- For repeat RF/anti-CCP or dsDNA testing, document why additional tests are clinically necessary and align with the allowed frequency limits.
Notes on AVISE (Exagen) two‑tiered testing and coverage
AVISE tests from Exagen use a two-tiered method and an algorithm measuring multiple SLE-relevant markers (including ANA, anti-dsDNA, anti-Sm, and cell-bound complement activation products) to produce an index intended to assist in SLE differential diagnosis and to support use in ANA-positive patients with clinical suspicion of lupus; note that these proprietary AVISE LDTs are listed among tests that do not meet coverage criteria.
- AVISE CTD/AVISE Lupus: two-tiered algorithm measuring ~10 SLE-relevant biomarkers (includes ENA panel, anti-dsDNA, anti-Sm, CB-CAPs such as BC4d/EC4d) and intended to assist diagnosis in ANA-positive patients with clinical suspicion of lupus.
- Policy position: use of cell-bound complement activation products (e.g., AVISE Lupus) and AVISE proprietary panels DOES NOT MEET COVERAGE CRITERIA.
Other proprietary molecular and multi‑biomarker tests — intended uses
Recognize other proprietary molecular and multibiomarker tests (PrismRA, Vectra DA, aiSLE DX, Seronegative RA Profile) by their intended use: PrismRA predicts likelihood of TNFi non-response using an MSRC; Vectra DA (MBDA) provides a 1–100 disease activity score derived from 12 serum biomarkers to complement clinical assessment; aiSLE DX assesses soluble immune mediators for SLE disease activity. These proprietary tests are explicitly identified in the policy and, unless otherwise covered, are subject to the policy's exclusions.
- PrismRA (MSRC): molecular signature classifier using 23 RNA features plus clinical variables to predict TNFi non-response prior to treatment.
- Vectra DA (MBDA): combines 12 serum biomarkers into a 1–100 score (≤29 low; 29–44 moderate; >44 high) intended to complement symptom-based disease activity measures.
- aiSLE DX: blood test measuring immune mediators to distinguish active versus low/quiescent SLE disease activity.
- Policy classification: PrismRA and Vectra DA are included in the policy's proprietary test discussion; serum biomarker panels for diagnosis/management DO NOT MEET COVERAGE unless specifically stated.
Authorization and billing notes — no special prior‑auth procedures specified
The policy does not specify separate prior authorization, medical necessity submission forms, or billing procedures for proprietary or multibiomarker tests; instead the document focuses on clinical validation, intended use, and whether tests meet coverage criteria.
- No specific prior authorization or billing workflow for PrismRA, MBDA, or other proprietary tests is provided in this policy text.
- Provider determinations should be guided by clinical validation and the coverage statements within the policy.
Follow applicable LCD/NCD or state Medicaid policy when conflicts exist
If this policy conflicts with any applicable government coverage determinations (e.g., LCDs, NCDs, or state Medicaid rules), follow the government policy to determine coverage for the affected individual.
- When a conflict exists between this Policy and relevant government policy (LCD/NCD/state Medicaid), government policy prevails for determinations.
- Refer to CMS Medicare Coverage Database or applicable state Medicaid resources for current government guidance.
Definitions and Abbreviations
Evidence, Validation, and Guideline Context
This policy synthesizes evidence and guideline positions on the clinical utility and validation of biomarker testing in systemic autoimmune rheumatic disease (SARD). Guideline bodies and specialty groups endorse HEp-2 IIF (ANA IIF) as the reference screening method because of its sensitivity for a broad range of autoantigens; reflex testing to ENA or anti-dsDNA is supported when clinical correlation and elevated ANA titres are present. Multiple guideline statements caution against ordering ANA subserologies without a positive ANA and compatible clinical signs, and note that multi-biomarker assays are not incorporated into routine guideline-recommended diagnostic pathways for RA or SLE management at this time (ACR, EULAR/ACR SLE classification references).
Proprietary multi-analyte panels and molecular classifiers (for example, AVISE/CB-CAP panels, PrismRA/MSRC, and MBDA/Vectra DA) have variable levels of analytic and clinical validation. PrismRA (MSRC) demonstrated strong positive predictive value and specificity in the CERTAIN prospective validation cohort (PPV 89.7%, specificity 86.8%, sensitivity 50%) and had supporting integrated analyses (NETWORK-004) showing increased odds of inadequate TNFi response (OR 4.1). Modeling and decision-impact surveys suggest potential clinical and economic value for PrismRA (e.g., projected 19% reduction in costs of ineffective treatment and clinician receptivity), but sensitivity and other performance caveats temper broad adoption.
MBDA/Vectra DA is analytically derived from a 12-biomarker algorithm that correlates with DAS28-CRP (r=0.72) and has been validated for disease activity assessment and prognostic risk of radiographic progression in some cohorts. Studies report that MBDA results can change treatment plans in observational settings (treatment-plan change rates reported), and adjusted MBDA scores (accounting for age, sex, adiposity) improved prognostic performance for radiographic progression. However, randomized data indicate MBDA may be insufficiently responsive compared with standard clinical disease activity measures in certain intervention trials, and scores can be influenced by BMI, age, and comorbidities.
Taken together, evidence supports selective, guideline-concordant use of traditional biomarkers (ANA by IIF, ENA subserologies when indicated, RF and anti-CCP for suspected RA, CRP/ESR for inflammation) while recognizing complementary roles for validated multi-biomarker tests in specific contexts (e.g., predicting TNFi non-response or assessing radiographic risk) rather than as replacements for clinical assessment. The policy therefore restricts routine coverage of proprietary serum biomarker panels for diagnosis, prognosis, or routine monitoring, while acknowledging validated clinical performance metrics and potential decision impact in narrower use-cases.
Key guideline sources and evidence cited in this policy include international clinical guidance and specialty society positions: the National Institute for Health and Care Excellence (NICE) recommendations on referral, testing and early management of suspected persistent synovitis (including guidance to test for rheumatoid factor and consider anti-CCP when indicated), the British Columbia RA guideline noting CRP/ESR as preferred inflammatory tests with limited specificity and commenting on RF/anti-CCP performance, and the Royal Australian College of General Practitioners guidance recommending baseline investigations (ESR/CRP, RF, anti-CCP) for patients with suspected RA.
Specialty society positions such as the American College of Rheumatology (ACR) reaffirm HEp-2 IIF as the preferred ANA screening method and advise against ordering ANA subserologies without a positive ANA and compatible clinical features; recent ACR RA management guidance does not endorse routine use of multi-biomarker or algorithmic tests for diagnostic or management indications.
Evidence references supporting biomarker test performance and decision-impact analyses are included in the scientific background and biomarker analysis sections. Notable studies cited include the CERTAIN and NETWORK-004 evaluations of PrismRA/MSRC (clinical validation and integrated analyses showing PPV, specificity, sensitivity, and odds ratios for TNFi non-response), analytic and clinical studies of MBDA/Vectra DA (developmental biomarker list, correlation with DAS28-CRP, prognostic analyses and responsiveness trials), and multiple observational, modeling, and decision-impact publications that informed the policy's assessment of clinical utility.
Billing and coding guidance referenced in the policy lists applicable CPT/HCPCS and proprietary U-codes for autoimmune rheumatic disease biomarker assays (for example, 81490 for Vectra®DA and numerous immunology codes such as 86038–86039, 86225, 86235, 86430–86431), which are presented for administrative completeness and do not imply unrestricted coverage of proprietary panels.
Policy Revision History
Initial publication / effective date listed as Initial Presentation Date.
Document revision with updated effective date, last review, and next review set to 2025-07-01.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.